Compare Cadila Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 22.4 21.2 105.9% View Chart
P/BV x 2.7 2.3 118.7% View Chart
Dividend Yield % 1.3 0.7 181.8%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
SUN PHARMA
Mar-19
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs432679 63.7%   
Low Rs306375 81.6%   
Sales per share (Unadj.) Rs128.6121.1 106.2%  
Earnings per share (Unadj.) Rs18.513.4 138.7%  
Cash flow per share (Unadj.) Rs24.420.7 117.9%  
Dividends per share (Unadj.) Rs3.502.75 127.3%  
Dividend yield (eoy) %0.90.5 181.6%  
Book value per share (Unadj.) Rs101.5172.6 58.8%  
Shares outstanding (eoy) m1,023.742,399.26 42.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.4 66.0%   
Avg P/E ratio x19.939.4 50.5%  
P/CF ratio (eoy) x15.125.5 59.4%  
Price / Book Value ratio x3.63.1 119.2%  
Dividend payout %18.920.6 91.8%   
Avg Mkt Cap Rs m378,1701,264,650 29.9%   
No. of employees `00012.417.5 71.1%   
Total wages/salary Rs m21,24159,671 35.6%   
Avg. sales/employee Rs Th10,585.016,608.1 63.7%   
Avg. wages/employee Rs Th1,707.83,409.6 50.1%   
Avg. net profit/employee Rs Th1,526.51,833.8 83.2%   
INCOME DATA
Net Sales Rs m131,656290,659 45.3%  
Other income Rs m2,01110,255 19.6%   
Total revenues Rs m133,667300,914 44.4%   
Gross profit Rs m29,73163,076 47.1%  
Depreciation Rs m5,98617,533 34.1%   
Interest Rs m1,9355,553 34.8%   
Profit before tax Rs m23,82150,246 47.4%   
Minority Interest Rs m4690-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m5,3036,009 88.3%   
Profit after tax Rs m18,98732,093 59.2%  
Gross profit margin %22.621.7 104.1%  
Effective tax rate %22.312.0 186.2%   
Net profit margin %14.411.0 130.6%  
BALANCE SHEET DATA
Current assets Rs m84,981310,692 27.4%   
Current liabilities Rs m73,425173,396 42.3%   
Net working cap to sales %8.847.2 18.6%  
Current ratio x1.21.8 64.6%  
Inventory Days Days7599 75.3%  
Debtors Days Days110112 98.2%  
Net fixed assets Rs m133,493232,477 57.4%   
Share capital Rs m1,0242,399 42.7%   
"Free" reserves Rs m102,839411,691 25.0%   
Net worth Rs m103,863414,091 25.1%   
Long term debt Rs m39,49715,226 259.4%   
Total assets Rs m234,831646,938 36.3%  
Interest coverage x13.310.0 132.5%   
Debt to equity ratio x0.40 1,034.2%  
Sales to assets ratio x0.60.4 124.8%   
Return on assets %8.95.8 153.1%  
Return on equity %18.37.8 235.9%  
Return on capital %18.310.2 179.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,40466,025 73.3%   
Fx outflow Rs m11,59338,610 30.0%   
Net fx Rs m36,81127,415 134.3%   
CASH FLOW
From Operations Rs m28,82321,965 131.2%  
From Investments Rs m-57,387-6,813 842.4%  
From Financial Activity Rs m18,846-27,305 -69.0%  
Net Cashflow Rs m-7,105-8,442 84.2%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; FMCG and Metal Stocks Gain(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 2% while the Hang Seng is down 0.3%.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 25, 2020 11:45 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - DR. REDDYS LAB COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS